Abstract
The objective of this study was to undertake a systematic review to assess the efficacy
of botulinum toxin therapy (BTX) for temporomandibular joint disorders (TMDs). A comprehensive
search of major databases through PubMed, EMBASE, and Cochrane CENTRAL was conducted
to locate all relevant articles published from inception to October 2014. Eligible
studies were selected based on inclusion criteria and included English language, peer-reviewed
publications of randomized controlled trials comparing BTX versus any alternative
intervention or placebo. Quality assessment and data extraction were done according
to the Cochrane risk of bias tool and recommendations. The entire systematic search
and selection process was done independently by two reviewers. Five relevant study
trials were identified, involving 117 participants. Two trials revealed a significant
between-group difference in myofascial pain reduction, another trial that compared
BTX with fascial manipulation showed equal efficacy of pain relief on TMDs, while
the remaining two trials showed no significant difference between the BTX and placebo
groups. Because of considerable variations in study methods and evaluation of results,
a meta-analysis could not be performed. Based on this review, no consensus could be
reached on the therapeutic benefits of BTX on TMDs. A more rigorous design of trials
should be carried out in future studies.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to International Journal of Oral and Maxillofacial SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Meta-analysis of treatment need for temporomandibular disorders in adult nonpatients.J Orofac Pain. 2008; 22: 97-107
- Temporomandibular joint disorders.Am Fam Physician. 2007; 76: 1477-1482
- Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique.J Craniomandib Disord. 1992; 6: 301-355
- Review of temporomandibular joint pathology. Part I: Classification, epidemiology and risk factors.Med Oral Patol Oral Cir Bucal. 2007; 12: E292-E298
- Topical review: new insights into the pathology and diagnosis of disorders of the temporomandibular joint.J Orofac Pain. 2004; 18: 181-191
- Hypothesis on a cause of temporomandibular joint disorders.Plast Reconstr Surg. 2003; 111: 2473-2474
- A prospective investigation over two decades on signs and symptoms of temporomandibular disorders and associated variables. A final summary.Acta Odontol Scand. 2005; 63: 99-109
- Risk factors for diagnostic subgroups of painful temporomandibular disorders (TMD).J Dent Res. 2002; 81: 284-288
- Pre- and post-synaptic actions of botulinum toxin at the rat neuromuscular junction.J Physiol. 1981; 317: 487-495
- Botulinum toxin injection of eye muscles to correct strabismus.Trans Am Ophthalmol Soc. 1981; 79: 734-770
- A critical review of the use of botulinum toxin in orofacial pain disorders.Dent Clin North Am. 2007; 51 (ix): 245-261
- Botulinum toxin in the treatment of myofascial pain syndrome.Pain. 1994; 59: 65-69
- Botulinum toxin therapy for myofascial pain disorders.Curr Pain Headache Rep. 2002; 6: 355-360
- A closer look to botulinum neurotoxin type A-induced analgesia.Toxicon. 2013; 71: 134-139
- Treatment of temporomandibular disorders with botulinum toxin.Clin J Pain. 2002; 18: S198-S203
- The emerging role of botulinum toxin in the treatment of temporomandibular disorders.Oral Dis. 2007; 13: 253-260
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.Br Med J. 2009; 339: b2535
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.Br Med J. 2011; 343: 5928
- Efficacy of botulinum toxin type A for treatment of persistent myofascial TMD pain: a randomized, controlled, double-blind multicenter study.Pain. 2011; 152: 1988-1996
- Myofascial pain of the jaw muscles: comparison of short-term effectiveness of botulinum toxin injections and fascial manipulation technique.Cranio. 2012; 30: 95-102
- Effect of botulinum toxin-A in myofascial pain patients with or without functional disc displacement.J Oral Maxillofac Surg. 2008; 66: 1644-1651
- Type A botulinum toxin in the treatment of chronic facial pain associated with masticatory hyperactivity.J Oral Maxillofac Surg. 2003; 61: 774-778
- Randomized controlled trial of botulinum toxin A for chronic myogenous orofacial pain.Pain. 2002; 99: 465-473
- The use of botulinum toxin for the treatment of temporomandibular disorder.Oral Health. 1998; 88: 32-37
- The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings.J Oral Maxillofac Surg. 1999; 57 (discussion 920–1): 916-920
- Temporal relationship of muscle weakness and pain reduction in subjects treated with botulinum toxin A.J Pain. 2003; 4: 159-165
- Botulinum toxin for the treatment of temporomandibular joint disk disfigurement: clinical experience.J Craniofac Surg. 2005; 16: 476-481
- Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study.Br J Oral Maxillofac Surg. 2013; 51: 199-205
- Botulinum toxin in pain treatment.Rev Bras Anestesiol. 2009; 59: 366-381
- Uses of botulinum toxin injection in medicine today.Br Med J. 2000; 320: 161-165
- Hyperhidrosis treated by botulinum A exotoxin.Dermatol Surg. 1998; 24: 1237-1241
- Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects.Expert Opin Investig Drugs. 2001; 10: 1531-1544
Article info
Publication history
Published online: April 25, 2015
Accepted:
April 7,
2015
Identification
Copyright
© 2015 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
